Osteo-Joint Therapy


120 Tablets  Glucosamine Hydrochloride

  • Fights Osteoarthritis*
  • Improves overall joint functioning and movement*
  • Reduces joint pain, swelling and stiffness*


• Helps to reduce osteoarthritis pain in joints: knees, hips, neck, wrist and ankles.
• Plays a key role in building healthy cartilage and connective tissues
• Improves general joint functioning. 
• Reduces joint swelling and stiffness
• Fights loss of movement
• Relieves osteoarthritis symptoms for up to 3 months after stopping treatment. 

Biogenique Doloflex is a synergic combination of natural compounds that complement each other to provide optimal therapeutic benefits to those suffering from osteoarthritis or general joint pain and swelling. It is an effective, natural, alternative treatment for those currently using non-steroidal anti-inflammatory agents. 

Why Biogenique?

The application of Structurally Active-Orthogenic (SAO) technology by Biogenique’s research and production team ensures that all available products are of a heightened quality. 

SAO technology produces active ingredients with strong molecular composition and the highest bioavailability (ratio of inactive/active ingredients) in order to ensure synergistic applications occur within the body. In other words, the Biogenique label ensures that all our products are able to be optimally absorbed by the bloodstream at the molecular level, and don’t just pass through the body undigested. 

Biogenique is pharmaceutically tested and clinically verified by careful examination at every stage of production. The protocols are measured and confirmed for international standard compliance before the product is introduced to market. 

Biogenique only uses 100% natural ingredients. 

Active Ingredients

Glucosamine Hydrochloride (Shrimp Exoskeleton)………......…………….375mg
Chondroitin Sulfate (Bos Taurus Cartilage)……...……………….………….150 mg
MSM (Dimethyl Sulfone)……………………………………………………….250 mg
Hyaluronic Acid (Hyaluronic Acid, Gallus Gallus -Comb)………………....5.25 mg
Vitamin C (Calcium Ascorbate ……………………………………………….62.5 mg
Chicken Cartilage………………………………………………………..…..…0.1 mg
Manganese (Manganese Ascorbate)…………………………….....……….0.5 mg
Chinese Skullcap (Scutellaria Baicalensis, Root)……….…………………125 mg 



120 Tablets 

Active Ingredients

Glucosamine Hydrochloride (Shrimp Exoskeleton)………......…………….375mg
Chondroitin Sulfate (Bos Taurus Cartilage)……...……………….………….150 mg
MSM (Dimethyl Sulfone)……………………………………………………….250 mg
Hyaluronic Acid (Hyaluronic Acid, Gallus Gallus -Comb)………………....5.25 mg
Vitamin C (Calcium Ascorbate ……………………………………………….62.5 mg
Chicken Cartilage………………………………………………………..…..…0.1 mg
Manganese (Manganese Ascorbate)…………………………….....……….0.5 mg
Chinese Skullcap (Scutellaria Baicalensis, Root)……….…………………125 mg 


Other Ingredients

Vegetable Cellulose-Microcrystalline, Vegetable Croscarmellose Sodium, Povidone (Vegetable Grade), Vegetable Silicon Dioxide, Vegetable Magnesium Stearate, Vegetable Hypromellose, Vegetable Glyceryl Triacetate, Vegetable Hydroxypropyl Cellulose, Talc, Titanium Dioxide (Vegetable grade), Riboflavin (Natural Color Additive)

Cautions & Warnings

Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if: you are diabetic, have a liver disorder, a history of kidney stones, or are currently taking blood thinners. 


Adults: 1-2 Tablets daily with food. 

Keep out of reach of children. 

NPN: 80044762


Biogenique Structurally Active-Orthogenic (SAO) technology

Biogenique SAO technology formulates Doloflex film coated tablet with synergic combination of natural compounds which are normally found in healthy cartilage. The combination consists of glucosamine hydrochloride, chondroitin sulfate, hyaluronic acid, manganese, MSM and vitamin C as an active ingredients. SAO technology found that these compounds complement each other. Use of this complementary therapy provides therapeutic effect together in single dose. They give maximum benefits and are absorbed readily with complete utility when combined, as compared to when taken separately. 

SAO Analysis

Glucosamine hydrochloride
Glucosamine in the body is used to make a “cushion” that surrounds the joints. In osteoarthritis, this cushion becomes thinner and stiff. Taking glucosamine hydrochloride as a supplement might help to supply the materials needed to rebuild the cushion. Glucosamine might directly stimulate the chondrocytes, which are cells that build and support cartilage in your joints. Other potential mechanisms of action include incorporation of important sulfur molecules into cartilage, down-regulation of genes that promote the degeneration of cartilage or replacement of critical joint constituents, such as keratan sulfate or hyaluronic acid. Glucosamine is often taken with chondroitin, another supplement thought to be effective in treating OA. Like glucosamine, chondroitin also has conflicting results in studies. 

Chondroitin sulfate

Chondroitin is a molecule that occurs naturally in the body. It is a major component of cartilage -- the tough, connective tissue that cushions the joints. Chondroitin helps keep cartilage healthy by absorbing fluid (particularly water) into the connective tissue. It may also block enzymes that break down cartilage, and it provides the building blocks for the body to produce new cartilage. Chondroitin is often taken with glucosamine, another supplement that has been studied along with chondroitin for OA. Like chondroitin, glucosamine also has conflicting results. 

Dimethylsulfone (MSM)

MSM is a chemical found in plants, animals, and humans. It can also be made in a laboratory. MSM is thought to work by contributing sulfur. It might supply sulfur to make other chemicals in the body and is believed to strengthen collagen. MSM may reduce osteoarthritis pain. MSM is often combined with glucosamine in commercial arthritis products. 


Manganese is a mineral element that is both nutritionally essential and potentially toxic. Manganese deficiency results in abnormal skeletal development in a number of animal species. Manganese is the preferred cofactor of enzymes called glycosyltransferases; these enzymes are required for the synthesis of proteoglycans that are needed for the formation of healthy cartilage and bone. 

Scientific Evidence

Knee osteoarthritis (mild-to-moderate)

Based on human research, there is good evidence to support the use of glucosamine hydrochloride in the treatment of mild-to-moderate knee osteoarthritis. Although some studies of glucosamine have not found benefits, these have either included patients with severe osteoarthritis or used products other than glucosamine hydrochloride . The evidence for the effect of glycosaminoglycan polysulphate is conflicting and merits further investigation. More well-designed clinical trials are needed to confirm safety and effectiveness, and to test different formulations of glucosamine. 

Osteoarthritis (general)

Several human studies and animal experiments report benefits of glucosamine in treating osteoarthritis of various joints of the body, although the evidence is less plentiful than that for knee osteoarthritis. Some of these benefits include pain relief, possibly due to an anti-inflammatory effect of glucosamine, and improved joint function. Overall, these studies have not been well designed. Chondroitin is frequently used with glucosamine. Multiple controlled clinical trials have examined the use of oral chondroitin in patients with osteoarthritis of the knee and other locations (spine, hips, finger joints). Most of these studies have reported significant benefits in terms of symptoms (such as pain), function (such as mobility), and reduced medication requirements (such as anti-inflammatories). Although there is some promising research, more study is needed in this area before a firm conclusion can be made. 

Pain (leg pain)

Preliminary human research reports benefits of injected glucosamine plus chondroitin in the treatment of leg pain arising from advanced lumbar degenerative disc disease. Further scientific evidence is necessary before a firm recommendation can be made. 

Rehabilitation (after knee injury)

Glucosamine has been given to athletes with acute knee injuries. Although glucosamine did not improve pain, it did help improve flexibility. Additional research is needed to confirm these early findings. 

Rheumatoid arthritis

Early human research reports benefits of glucosamine in the treatment of joint pain and swelling in rheumatoid arthritis. In other research, glucosamine did not exert anti-rheumatic effects, but it did improve symptoms of the disease. However, this is early information, and additional research is needed before a conclusion can be drawn. The treatment of rheumatoid arthritis can be complicated, and a qualified healthcare provider should follow patients with this disease. 


• Because of the potential for side effects and interactions with medications, Doloflex Film Coated tablet should be taken only under the supervision of a knowledgeable health care provider 

• Studies suggest that glucosamine is safe, and causes only minor side effects, such as stomach upset, heartburn, indigestion, gas, bloating, nausea, and diarrhea. If these occur, try taking glucosamine with food.

• People with diabetes should have their blood sugar checked regularly. Glucosamine chondroitin may cause insulin to work less effectively.

• Doloflex is made from shellfish, cow cartilage etc. so people with shellfish allergies should check with a health care professional before taking them. Even if you are a vegetarian, look for a supplement made from algae instead.

• Pregnant and breastfeeding women should not take Doloflex, since it has not been studied for safety in these groups.

• Glucosamine may raise blood pressure and cholesterol levels. See your doctor regularly to have these levels checked while you are taking glucosamine.

• There is some concern that glucosamine and chondroitin may increase exacerbations in some patients with asthma. 

Interactions you should know about

• If you are currently being treated with any of the following medications, you should first talking to your doctor before taking Doloflex film coated tablets

• Warfarin (Coumadin) -- Glucosamine may increase the blood thinning effect of coumadin and may increase the risk of bruising or bleeding, which can be serious. Speak with your physician.

• Anticoagulants (blood thinners) -- Because chondroitin is similar to heparin, a drug used to thin the blood, it is theoretically possible for chondroitin to enhance the effects of blood-thinning medications. Chondroitin could also enhance the blood-thinning effects of vitamins and supplements such as fish oil and vitamin E.

• Non-steroidal anti-inflammatory drugs (NSAIDs) -- If you take NSAIDs to relieve the pain of OA, taking Doloflex Film Coated tablet may reduce the dose of NSAIDs you need to take. Since NSAIDs can cause stomach bleeding, reducing the dosage can be helpful. Talk to your doctor, however, before starting to take Doloflex, since it can take several months before you experience any improvements.

• Blood sugar lowering medications or insulin -- Glucosamine may change the dose needed for blood sugar lowering medications and insulin. If you take these medications for diabetes, talk to your doctor before taking glucosamine. 

Selected references

1. Albert SG, Oiknine RF, Parseghian S, et al. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. Diabetes Care 2007 Nov;30(11):2800-3.

2. Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes 2006 Nov;55(11):3142-50.

3. Audimoolam VK, Bhandari S. Acute interstitial nephritis induced by glucosamine. Nephrol Dial Transplant 2006 Jul;21(7):2031.

4. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006 Feb 23;354(8):795-808.

5. Cohen M, Wolfe R, Mai T, et al. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003;30(3):523-528.

6. Felson DT. Glucosamine and chondroitin sulfate in knee osteoarthritis: where now? Nat Clin Pract Rheumatol 2006;2(7):356-357.

7. Leffler CT, Philippi AF, Leffler SG, et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999;164(2):85-91.

8. Mazieres B, Hucher M, Zaim M, et al. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007;66(5):639-645.

9. McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283(11):1469-1475.

10. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005 Mar;52(3):779-86.

11. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163(13):1514-1522.

12. Nakamura H, Masuko K, Yudoh K, et al. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int 2007 Jan;27(3):213-8. 

I) Evaluation of intra-articular hyaluronan, sodium chondroitin sulfate and N-acetyl-d-glucosamine combination versus saline (0.9% NaCl) for osteoarthritis using an equine model.


Equine Orthopedic Research Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523, USA. Electronic address: 


A randomized blinded placebo controlled trial was conducted to assess the clinical, biochemical and histological effects of a hyaluronan, sodium chondroitin sulfate and N-acetyl-d-glucosamine combination (PG) administered through an intra-articular (IA) route for the treatment of osteoarthritis (OA) at the time of injury. OA was induced in one carpal joint of each of 16 horses. Horses were designated placebo or IA PG treated. All horses were treated with 125mg amikacin sulfate IA and 5mL physiological saline in the middle carpal joint bilaterally on study Days 0 (after induction of OA), 7, 14 and 28, except the OA affected joint of the IA PG horses, which received 5mL PG plus 125mg of amikacin sulfate on similar days. Evaluations included clinical and radiographic, synovial fluid analysis, gross and histological examinations, as well as histochemical and biochemical analyses. The model induced a significant pathology that resulted in clinical disease. No adverse treatment-related events were detected in any of the horses. Intra-articular treatment of OA-affected joints with PG resulted in a transient 16% improvement in clinical pain (lameness scores) and evidence of improvement trends in bone proliferation radiographically as well as in the degree of full thickness articular cartilage erosion seen grossly when compared to placebo treated OA affected joints, although the vast majority of outcome parameters were not significantly different than controls. The findings support some potential clinical sign or disease modifying action of this compound administered IA at the tested dose and frequency. 

II) Use of glucosamine and chondroitin supplements and risk of colorectal cancer.


Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N., Mailbox M4-B402, Seattle, WA 98109, USA. 



Glucosamine and chondroitin are non-vitamin, non-mineral supplements which have anti-inflammatory properties. These supplements are typically used for joint pain and osteoarthritis and are commonly taken as either glucosamine alone or glucosamine plus chondroitin. An exploratory analysis conducted within the VITamins And Lifestyle (VITAL) study observed any use of glucosamine and chondroitin to be associated with reduced risk of colorectal cancer (CRC) after 5 years of follow-up. 


With two additional years of follow-up, we have studied these associations in greater depth, including associations by frequency/duration of use and by formulation, and have evaluated whether observed associations are modified by factors associated with inflammation. Participants include 75,137 western Washington residents aged 50-76 who completed the mailed VITAL questionnaire between 2000 and 2002. Use of glucosamine and chondroitin was ascertained by questions about supplement use during the 10-year period prior to baseline, and participants were followed for CRC through 2008 (n = 557). Cox regression was used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs). 


Persons reporting use of glucosamine + chondroitin on 4+ days/week for 3+ years had a non-statistically significant 45 % lower CRC risk than non-users (HR: 0.55; 95 % CI 0.30-1.01; p-trend: 0.16). This association varied by body mass index (p-interaction: 0.006), with inverse association observed among the overweight/obese (p-trend: 0.02), but not among the underweight/normal weight. Use of glucosamine alone was not significantly associated with CRC risk. 


There is great need to identify safe and effective cancer preventive strategies, suggesting that glucosamine and chondroitin may merit further attention as a potential chemopreventive agent. 

III) Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.


Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. 



Many women with hormone receptor-positive breast cancer discontinue effective aromatase inhibitor (AI) treatment due to joint symptoms. 


We conducted a single-arm, open-label, phase II study evaluating glucosamine-sulfate (1,500 mg/day) + chondroitin-sulfate (1,200 mg/day) for 24 weeks to treat joint pain/stiffness in postmenopausal women with early stage breast cancer who developed moderate-to-severe joint pain after initiating AIs. The primary endpoint was improvement in pain/stiffness at week 24 assessed by the Outcome Measure in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria. Secondary endpoints assessed changes in pain, stiffness, and function using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index for hips/knees and the Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (M-SACRAH) for hands/wrists. The Brief Pain Inventory (BPI) assessed pain interference, severity, and worst pain. 


Of 53 patients enrolled, 39 were evaluable at week 24. From baseline to week 24, 46 % of patients improved according to OMERACT-OARSI criteria. At week 24, there were improvements (all P < 0.05) in pain and function as assessed by WOMAC and M-SACRAH, and in pain interference, severity, and worst pain as assessed by BPI. Estradiol levels did not change from baseline. The most commonly reported side effects were headache (28 %), dyspepsia (15 %), and nausea (17 %). 


In this single-arm study, 24 weeks of glucosamine/chondroitin resulted in moderate improvements in AI-induced arthralgias, with minimal side effects, and no changes in estradiol levels. These results suggest a need to evaluate efficacy in a placebo-controlled trial. 

IV) Use of glucosamine and chondroitin in relation to mortality.


Cancer Prevention Program, The Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 


Glucosamine and chondroitin are products commonly used by older adults in the US and Europe. There is limited evidence that they have anti-inflammatory properties, which could provide risk reduction of several diseases. However, data on their long-term health effects is lacking. To evaluate whether use of glucosamine and chondroitin are associated with cause-specific and total mortality. Participants (n = 77,510) were members of a cohort study of Washington State (US) residents aged 50-76 years who entered the cohort in 2000-2002 by completing a baseline questionnaire that included questions on glucosamine and chondroitin use. Participants were followed for mortality through 2008 (n = 5,362 deaths). Hazard ratios (HR) for death adjusted for multiple covariates were estimated using Cox models. Current (baseline) glucosamine and chondroitin use were associated with a decreased risk of total mortality compared to never use. The adjusted HR associated with current use of glucosamine (with or without chondroitin) was 0.82 (95 % CI 0.75-0.90) and 0.86 (95 % CI 0.78-0.96) for chondroitin (included in two-thirds of glucosamine supplements). Current use of glucosamine was associated with a significant decreased risk of death from cancer (HR 0.87 95 % CI 0.76-0.98) and with a large risk reduction for death from respiratory diseases (HR 0.59 95 % CI 0.41-0.83). Use of glucosamine with or without chondroitin was associated with reduced total mortality and with reductions of several broad causes of death. Although bias cannot be ruled out, these results suggest that glucosamine may provide some mortality benefit. 


Customers who bought this item also bought: